Factors influencing the efficacy of IFN and ribavirin therapy were not clear. We investigated gene polymorphisms of non-responders (NR).
(Patients) Sixty-six chronic hepatitis patients with HCV received the combined therapy of IFN and ribavirin. Gene polymorphisms of IL-10 promoter region, MxA promoter region, TNF-α promoter region and TNF-β Nco1 site were studied.
(Results) In patients with serotype 2, NR was significantly decreased, compared to transient responders (TR) or sustained responders (SR). The amount of HCV was not associated with the effectiveness. The frequency of severe fibrosis in NR was higher than that in TR and SR. There was no association of gene polymorphisms with IL-10 promoter region, MxA promoter region or TNF-α promoter region. In TNF-β gene polymorphism, B2/B2 frequency was significantly increased in NR, compared with TR and SR.
(Conclusion) Serotype, liver fibrosis and TNF-β gene polymorphism might be associated with non-responders to the combined therapy.
View full abstract